Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme

J Nelissen, P Lemkens, H Sann, M Bindl, F Bassissi, D Jasserand, J G R De Mey, B J A Janssen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The pharmacological profile of the novel putative neutral endopeptidase (NEP) and endothelin converting enzyme (ECE) inhibitor SOL1 was examined.
Original languageEnglish
JournalLife Sciences
Volume91
Issue number13-14
Pages (from-to)587-592
ISSN2042-4329
DOIs
Publication statusPublished - 2012

Keywords

  • Animals
  • Aspartic Acid Endopeptidases
  • Benzazepines
  • Blood Pressure
  • Desoxycorticosterone
  • Disease Models, Animal
  • Enzyme Inhibitors
  • Half-Life
  • Humans
  • Hydrogen-Ion Concentration
  • Hypertension
  • Inhibitory Concentration 50
  • Male
  • Metalloendopeptidases
  • Mice
  • Mice, Inbred C57BL
  • Neprilysin
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Wistar
  • Sodium Chloride, Dietary
  • Tissue Distribution

Fingerprint

Dive into the research topics of 'Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme'. Together they form a unique fingerprint.

Cite this